The Dawn of a New Era in Oncology Treatment13 Oct 2025 08:55
Without question, the first successful clinical proof of efficacy in humans for Avacta’s pre|CISION® platform (FAP-activated chemo) would be the transformational event.
Here’s why:
If Avacta demonstrates in clinical trials that its pre|CISION® delivery mechanism can activate chemotherapy inside the tumour while sparing healthy tissue, that’s a paradigm shift in oncology.
This could make their platform licensable across dozens of oncology drugs — turning Avacta into a platform company, not just a single-drug developer.
Pharma companies would pay huge sums to license a proven tumour-activated delivery system for their own cytotoxics.
That sort of validation (backed by data) could push Avacta into the multi-billion-pound market cap bracket very quickly.